Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-21-063096
Filing Date
2021-05-07
Accepted
2021-05-07 16:17:20
Documents
46
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q tmb-20210331x10q.htm   iXBRL 10-Q 1074936
2 EXHIBIT 31.1 tmb-20210331xex31d1.htm EX-31.1 10194
3 EXHIBIT 31.2 tmb-20210331xex31d2.htm EX-31.2 11466
4 EXHIBIT 32.1 tmb-20210331xex32d1.htm EX-32.1 6199
5 EXHIBIT 32.2 tmb-20210331xex32d2.htm EX-32.2 5964
  Complete submission text file 0001104659-21-063096.txt   3964909

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA tmb-20210331.xsd EX-101.SCH 32750
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tmb-20210331_cal.xml EX-101.CAL 21528
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tmb-20210331_def.xml EX-101.DEF 137247
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE tmb-20210331_lab.xml EX-101.LAB 242635
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tmb-20210331_pre.xml EX-101.PRE 219596
11 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20210331x10q_htm.xml XML 542013
Mailing Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014 212-554-4366
Checkpoint Therapeutics, Inc. (Filer) CIK: 0001651407 (see all company filings)

EIN.: 472568632 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38128 | Film No.: 21902916
SIC: 2834 Pharmaceutical Preparations